1. Home
  2. TCBK vs DFTX Comparison

TCBK vs DFTX Comparison

Compare TCBK & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriCo Bancshares

TCBK

TriCo Bancshares

HOLD

Current Price

$49.12

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$22.40

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TCBK
DFTX
Founded
1975
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
TCBK
DFTX
Price
$49.12
$22.40
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$53.80
$38.50
AVG Volume (30 Days)
100.2K
2.0M
Earning Date
04-23-2026
05-04-2026
Dividend Yield
2.84%
N/A
EPS Growth
6.94
N/A
EPS
3.70
N/A
Revenue
$53,445,000.00
N/A
Revenue This Year
$12.03
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$13.69
N/A
Revenue Growth
4.12
N/A
52 Week Low
$37.80
$14.62
52 Week High
$53.18
$26.25

Technical Indicators

Market Signals
Indicator
TCBK
DFTX
Relative Strength Index (RSI) 50.27 60.63
Support Level $48.06 $16.37
Resistance Level $51.15 N/A
Average True Range (ATR) 1.07 1.39
MACD -0.02 0.04
Stochastic Oscillator 28.81 40.92

Price Performance

Historical Comparison
TCBK
DFTX

About TCBK TriCo Bancshares

TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: